Advertisement
YOU ARE HERE: LAT HomeCollectionsSequana Therapeutics Inc
IN THE NEWS

Sequana Therapeutics Inc

FEATURED ARTICLES
BUSINESS
November 4, 1997 | Reuters
Arris Pharmaceuticals Corp., a South San Francisco-based drug research and development firm, said it will acquire the genetic research company Sequana Therapeutics Inc. in a stock swap worth $166 million. After the news, shares of La Jolla-based Sequana jumped $2.69 to close at $13.94, while Arris lost 88 cents to close at $11.13, both on Nasdaq. Under terms of the agreement, Arris would issue 1.35 shares for each share of Sequana.
ARTICLES BY DATE
BUSINESS
November 4, 1997 | Reuters
Arris Pharmaceuticals Corp., a South San Francisco-based drug research and development firm, said it will acquire the genetic research company Sequana Therapeutics Inc. in a stock swap worth $166 million. After the news, shares of La Jolla-based Sequana jumped $2.69 to close at $13.94, while Arris lost 88 cents to close at $11.13, both on Nasdaq. Under terms of the agreement, Arris would issue 1.35 shares for each share of Sequana.
Advertisement
BUSINESS
January 21, 1997 | Times Staff and Wire Reports
La Jolla-based Sequana Therapeutics Inc. and Norwalk, Conn.-based Perkin-Elmer have signed a letter of intent to form a DNA-sequencing joint venture in Shanghai. The venture, to be called GeneCore BioTechnologies Inc., would provide large-scale, automated DNA analysis and gene sequencing services. Gene sequencing is used in the development of diagnostic tests and in the creation of drugs and industrial enzymes.
BUSINESS
September 3, 1997 | Bloomberg News
La Jolla-based Sequana Therapeutics Inc. said it will receive a milestone payment from Glaxo Wellcome for a study that identified regions of DNA that Sequana and Glaxo believe contain genes associated with diabetes. This will be the second payment from Glaxo Wellcome, which agreed to pay Sequana as much as $50 million if Glaxo Wellcome can develop a drug based on the research. Sequana would not disclose how much Glaxo Wellcome has already agreed to in milestone payments.
BUSINESS
May 7, 1996
Companies ranked by chance in stock price since 1995 initial offering. *--* Rank Company Offering Price Recent Price 1 DSP Communications Inc 10 30.5 2 Premisys Communications Inc 16 41.75 3 HNC Software Inc 14 36.5 4 Remedy Corp 23 67 5 Netscape Communications Corp 28 55.25 6 Arbor Software Corp 17 64 7 P-Com Inc 12 20.88 8 PDT Inc 16 54.5 9 Clarify Inc 13 40 10 Red Brick Sys Inc 18 55 11 Lumisys Inc 8 23.5 12 Verity Inc 12 31.5 13 Xylan Corp 26 64.
BUSINESS
April 29, 1996 | From Reuters
Millennium Pharmaceuticals Inc., hoping to capitalize on a firm market for biotechnology stocks as well as investor fascination with the prospects for an anti-obesity drug, plans to go public this week. The Cambridge, Mass.-based company will become the latest in the field of genomics--the study of genes--to go public in a market that has in recent months been receptive to biotech stocks.
BUSINESS
May 6, 1997
Companies ranked by net losses in 1996, including one-time charges that may not indicate routinely losing operations. *--* Rank Company 96 income (millions) 1 Apple Computer Inc. -$835 2 AST Research Inc. -418 3 Amdahl Corp. -327 4 Merisel Inc. -219 5 Calgene Inc. -145 6 Sizzler International -136 7 National Semiconductor -126 8 Advanced Micro Devices -115 9 SyQuest Technology Inc. -110 10 Argonaut Group Inc. -106 11 Trikon Technologies Inc. -94 12 Bay Networks Inc. -83 13 Cirrus Logic Inc.
Los Angeles Times Articles
|